<DOC>
	<DOCNO>NCT02637037</DOCNO>
	<brief_summary>This bioequivalence study compare 2 fixed-dose combination tablet dapagliflozin/metformin XR manufacture 2 different plant healthy subject fast feed condition</brief_summary>
	<brief_title>A Study Assess Bioequivalence Dapagliflozin/Metformin XR Fixed-dose Combination Tablets Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 , 2-part , open-label , randomize , 4-period , 4-treatment , crossover study healthy subject ( male females non-childbearing potential )</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedures 2 . Healthy male female subject age 18 55 year suitable vein cannulation repeat venipuncture 3 . Females must negative serum pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level postmenopausal range Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy , tubal ligation 4 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg inclusive screen 1 . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study 2 . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational medicinal product 4 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result , judge investigator 5 . Any clinically significant abnormal finding vital sign , judge investigator 6 . Any clinically significant abnormality 12lead ECG judge investigator 7 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) antibody 8 . Known suspected history drug abuse , judge investigator 9 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration IMP study . The period exclusion begin 3 month final dose . 10 . Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen 11 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class dapagliflozin/metformin XR . 12 . Current smoker smoke used nicotine product within 3 month prior screen 13 . Positive screen drug abuse , cotinine alcohol screen admission study center 14 . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP 15 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , vitamin mineral 2 week prior first administration IMP long medication long halflife 16 . Known suspected history alcohol abuse excessive intake alcohol judge investigator 17 . Involvement AstraZeneca study site employee close relatives 18 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement 19 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>dapagliflozin/metformin XR 5/500 mg</keyword>
	<keyword>dapagliflozin/metformin XR10/1000 mg</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>fix dose combination tablet</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>type 2 Diabetes Mellitus ( T2DM )</keyword>
	<keyword>safety</keyword>
</DOC>